Trial Profile
Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SWITCH-2
- 02 Oct 2017 Status changed from recruiting to discontinued.
- 25 Sep 2012 New trial record